David C Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE is an expert in Endocrinology at Mills Peninsula Health Services (United States). As of November 2026, ScienceLeadR ranks David C Klonoff in the top 1% of experts worldwide for Diabetes Mellitus, Glucose Metabolism Disorders and Continuous Glucose Monitoring. David C Klonoff has authored 478 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 1 of them ongoing. SLR score: 2,086 (community average: 125). How the SLR is computed.

LeadR Profile

Profile validated by the expert
David C Klonoff, MD, FACP, FRCP (Edin), Fellow AIMBE Mills Peninsula Health Services United States
2 086 ScienceLeadR Reputation 2086
Network Map

Endocrinology

Subspecialties: Public Health - Gastroenterology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Short Biography

David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Chair of the Endocrinology Research Advisory Committee at Sutter Health Research Institute, and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award. He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. He received the IEEE Standards Association Conformity Assessment Award in 2022. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology.He was named an Avant-garde All-Star in 2025 for being in the top 1% of US endocrinology researchers. He was ranked by ScienceLeadR in 2026 as being among the top 1% of experts worldwide in diabetes, continuous glucose monitoring, computer security, computing methodologies, and glucose metabolism disorders. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. Dr. Klonoff is a graduate of UC Berkeley, (Phi Beta Kappa, Junior Year) and UCSF Medical School (Alpha Omega Alpha, Junior Year.) His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals.

Organizations

Source: PubMed

University of California, San Francisco

2025 - 2025

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 478

Citations

Citations: 20 063 1st author: 93 Last author: 130 Unique author: 94


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial.
PMID 42747817 — glucagon-like peptide 1, quality of life, safety, cardiovascular diseases, frailty, semaglutide
JAMA Cardiol20262
Image-Based Dietary Assessment Using Multimodal Large Language Models: Performance, Limitations, and Clinical Applicability in Diabetes.
PMID 42996283 — diabetes mellitus, nutrients, language, diet, food, meals, carbohydrates, diet, healthy
medRxiv20260
DiaBench: A Benchmarking Framework to Evaluate the Performance of LLMs in T2D Patient Education.
PMID 42990471 — diabetes mellitus, education, patient education as topic, benchmarking
medRxiv20260
One Size Does Not Fit All: The Need for Sex-Specific Precision Medicine in Diabetes Technology.
PMID 40413613 — diabetes mellitus, exercise, menstrual cycle, insulin, puberty, aging, reproductive health, sex, precision medicine, research, menopause, gonadal steroid hormones
J Diabetes Sci Technol20252
Insulin pens and the digital ecosystem.
PMID 42776165 — diabetes mellitus, insulin, ecosystem, therapeutics
Diabetologia20261

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 11
N/A 5
Phase 2 2
Phase 4 2

By status:

Completed 19
Active not recruiting 1

By type:

Interventional 19
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 4
multicentric5to9 2
multicentricup10 12

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Continuous Glucose Monitoring in Intensive Care Unit
NCT05585801 — diabetes mellitus, research design, blood glucose, insulin, blood, biochemistry, point-of-care systems, insemination, artificial, heterologous, critical care, therapeutics, intensive care units, continuous glucose monitoring
N/AActive not recruiting2022

LeadR Networks

Main global connection map